Artelo Biosciences (NASDAQ:ARTL) Issues Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Artelo Biosciences (NASDAQ:ARTLGet Free Report) released its quarterly earnings results on Monday. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.27, Zacks reports.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $1.32 on Thursday. The firm has a fifty day moving average of $1.43 and a two-hundred day moving average of $1.42. The stock has a market capitalization of $4.26 million, a price-to-earnings ratio of -0.42 and a beta of 1.44. Artelo Biosciences has a 52 week low of $1.15 and a 52 week high of $2.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a report on Wednesday.

Get Our Latest Stock Report on Artelo Biosciences

About Artelo Biosciences

(Get Free Report)

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.

Featured Stories

Earnings History for Artelo Biosciences (NASDAQ:ARTL)

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with's FREE daily email newsletter.